Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00477113 · ClinicalTrials.gov registry record
TYSABRI Global Observational Program in Safety
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 2,207
- Enrollment target
NCT00477113: Completed study, sponsored by Biogen.
NCT00477113 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 2,207 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00477113 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 2,207 participants
- Enrollment target
Study Summary
The Primary objective of this study is to determine the incidence and pattern of serious infections, malignancies, and other serious adverse events (SAE) in participants with multiple sclerosis (MS) treated with Tysabri (natalizumab).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,207 participants |
| Start Date | 2007-01 |
| Est. Completion | 2015-05 |
What the finished NCT00477113 record still lists
NCT00477113 is an observational study that tracks outcomes without assigning an intervention. Its 2,207 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00477113 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00477113 about?
NCT00477113 is a clinical study titled "TYSABRI Global Observational Program in Safety". The Primary objective of this study is to determine the incidence and pattern of serious infections, malignancies, and other serious adverse events (SAE) in participants with multiple sclerosis (MS) treated with Tysabri (natalizumab).
What is the current status of trial NCT00477113?
This trial is currently completed. The enrollment target is 2,207 participants. The study started on 2007-01. Estimated completion is 2015-05.
Who is sponsoring clinical trial NCT00477113?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05654207 · 2,200 participants · NA
WeCare: A System of Care for Black Youth
- NCT06144554 · 2,200 participants
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
- NCT06526988 · 2,200 participants · NA
Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure
- NCT06682650 · 2,200 participants · NA
Implementation of a ColoRectal Cancer Screening Tool in US Primary Care Practices - Usual Quality Improvement (10 Clinics) vs Normalization Process Theory-Participatory Learning in Action (10 Clinics)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia